Abstract
Two main biological effects of prostacyclin, i.e., its effect on platelets and vasodilation, were already observed during the first intravenous administration of prostacyclin to man [5, 25] and were confirmed in later studies [7, 14]. The action of pros-tacyclin on platelets is manifested in its anti-aggregatory and disaggregatory properties [5, 18, 26]. The former are seen as a marked inhibition of ADP- or collagen-induced platelet aggregation in PRP, the latter as dispersion of both circulating platelet aggregates and platelet thrombi that have been formed on a collagen surface [18]. These effects are observed within first 15–45 min of infusion of prostacyclin (PGI2). However, after 24 hr, and usually after 72 hr of administration of PGI2, an unexpected activation of platelets is observed in patients who were treated with prostacyclin (2–5 ng/kg/min i.v.) (Fig. 1). Recently, Sinzinger et al. [16]. found in vivo a similar activation of platelets in patients with peripheral arterial disease who were treated with PGI2 (5 ng/kg/min) for a period of 8 days. A sudden decrease in platelet sensitivity to PGI2, increased β-thromboglobulin level in blood, increased circulating platelet factor 4 (PF4) were observed as soon as 24 hr after beginning of the therapy. This “rebound effect” of PGI2 on platelets is of an unknown mechanism but exhaustion of the platelet adenylate-cyclase system is one of possible explanations.
Keywords
- Central Retinal Vein Occlusion
- Stroke Volume Index
- Pulmonary Artery Hypertension
- Retinal Blood Vessel
- Arteriosclerosis Obliterans
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J. W. Aiken, R. R. Gorman, and R. J. Shebuski, Prostacyclin prevents blockage of partially obstructed coronary arteries, in: “Prostacyclin” ( J. R. Vane and S. Bergström, eds.), Raven Press, New York (1979).
J. M. Armstrong, D. Chapple, D. J. Dusting, R. Hughes, S. Moncada, and J. R. Vane, Cardiovascular actions of prostacyclin in chloralose anaesthetized dogs, Br. J. Pharmacol., 61: 36P (1977).
H. J. Dargie and P. J. Lewis, Effect of prostacyclin on angina at rest, in: “Clinical Pharmacology of Prostacyclin” ( P. J. Lewis and J. O’Grady, eds.), Raven Press, New York (1981).
T. M. Fitzpatrick, I. Alter, E. J. Corey, P. W. Ramwell, J. C. Rose, and P. A. Kot, Cardiovascular responses to PGI2 (Prostacyclin) in the dog, Circ. Res., 42: 192 (1978).
R. J. Gryglewski, A. Szczeklik, and R. Nizankowski, Anti-platelet action of intravenous infusion of prostacyclin in man, Thrombos. Res., 13: 153 (1978).
H. B. Hechturan, T. Utsunomiya, A. M. Vegas, G. A. Grindlinger, G. A. McLaughlin, M. M. Krausz, and D. Shepro, Prostaglandin mediation of pulmonary fibrinolytic activity, in: Symposium A. Einstein Coll. of Med., Raven Press, New York (in press).
V. Hossman, G. A. FitzGerald, A. Heinen, and H. Auel, Effect of prostacyclin on haemorrheology and haemostasis in obliterative arterial disease, in: “Clinical Pharmacology of Prostacyclin” ( P. J. Lewis and J. O’Grady, eds.), Raven Press, New York (1981).
P. J. Kadovitz, B. M. Chapnick, L. P. Feigen, A. L. Hyman, P. K. Nelson, and E. W. Spannhake, Pulmonary and systemic vasodilator effects of the newly discovered prostaglandin PGI2, J. Appl. Physiol.: Resp. Environm. Exerc. Physiol., 45 /3: 403 (1978).
A. M. Lefer and E. F. Smith III, Protective action of prostacyclin in myocardial ischemia and trauma, in: “Prostacylin” ( J. R. Vane and S. Bergström, eds.), Raven Press, New York (1979).
S. J. Machin, G. Defreyn, D. A. F. Chamone, and J. Vermylen, Clinical infusions of prostacylin in advanced arterial disease, in: “Clinical Pharmacology of Prostacyclin” ( P. J. Lewis and J. O’Grady, eds.), Raven Press, New York (1981).
A. Masseri, Pathogenetic mechanism of angina pectoris: expanding views, Br. Heart J., 43: 648 (1980).
R. N. McAlpin, Relation of coronary arterial spasm to site of organic stenosis, Am. J. Cardiol., 46: 143 (1980).
J. Mehta, P. Mehta, and G. J. Pepine, Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease, 3: Role of tachycardial stress and practolol. Circulation, 58: 881 (1978).
J. O’Grady, S. Warrington, M. J. Moti, S. Bunting, R. Flower, A. S. E. Higgs, E. A. Fowle, and S. Moncada, Effects of intravenous prostacyclin infusions in healthy volunteers - some preliminary observations, in: “Prostacyclin” ( J. R. Vane and S. Bergström, eds.), Raven Press, New York (1979).
Report on the Joint Int. Soc. and Fed. of Cardiology/WHO Task Force on Standardization of Clinical Nomenclature: Nomenclature and Criteria for Diagnosis of Ischemic Heart Disease, Circulation, 59: 697 (1979).
H. Sinzinger, K. Silberbauer, A. K. Harsch, and A. Gall, Decreased sensitivity of human platelets to PGI2 during longterm intraarterial prostacyclin infusion in patients with peripheral vascular disease - a rebound phenomenon, Prostaglandins, 21: 49 (1981).
E. W. Spannhake, B. W. Chapnick, L. P. Faigen, P. K. Nelson, A. L. Hyman, M. K. Carter, and P. J. Kadovitz, Pulmonary and systemic vasodilator effects of prostacyclin, Fed. Proc., 37: 731 (1978).
A. Szczeklik and R. J. Gryglewski, Actions of prostacyclin in man, in: “Prostacyclin” ( J. R. Vane and S. Bergström, eds.), Raven Press, New York (1979).
A. Szczeklik and R. J. Gryglewski, Low-density lipoproteins (LDL) are carriers for lipid peroxides and invalidate prostacyclin (PGI2) biosynthesis in arteries, Artery, 7: 488 (1980).
A. Szczeklik and R. J. Gryglewski, Treatment of vascular di-ease with prostacyclin, in: “Clinical Pharmacology of Prostacyclin” ( J. P. Lewis and J. O’Grady, eds.), Raven Press, New York (1980).
R. Nizankowski, Hemodynamic in: “Adv. Prostagl. Thrombox. R. Nizankowski, Hemodyanamic in man, Br. Heart J., 44: 254
A. Szczeklik, R. J. Gryglewski, E. Kostka-Trabka, R. Nizankowski, S. Skawinski, 0. Billewicz, P. Gluszko, J. Szczeklik, L. Grodzinska, A. Dembinska-Kiee, K. Bieron, and E. Telesz, Prostacyclin in treatment of peripheral vascular disease of lower extremities [in Polish], Przegl. Lek., 37: 659 (1980).
A. Szczeklik, R. J. Gryglewski, J. Musial, L. Grodzinska, M. Serwonska, and E. Marcinkiewicz, Thromboxane generation and platelet aggregation in survivals of myocardial infarction, Thrombos. Haemostas., 40: 66 (1978).
A. Szczeklik, R. J. Gryglewski, E. Nizankowska, R. Niankowski, and J. Musial, Pulmonary and anti-platelet effects of intravenous and inhaled prostacyclin in man, Prostaglandins, 16: 651 (1978).
A. Szczeklik, R. J. Gryglewski, R. Nizankowski, J. Musial, R. Pieton, and J. Mruk, Circulatory and anti-platelet effects of intravenous prostacyclin in healthy mean, Pharmacol. Res. Commun., 10: 545 (1978).
A. Szczeklik, R. J. Gryglewski, R. Nizankowski, S. Skawiriski, and P. Gluszko, Prostacyclin therapy of peripheral vascular disease, Thrombos. Res., 19: 191 (1980).
A. Szczeklik, R. Nizankowski, S. Skawiriski, J. Szczeklik, P. Gluszko, and R. J. Gryglewski, Successful therapy of advanced arteriosclerosis obliterans with prostacyclin, Lancet, 1: 1111 (1979).
A. Szczeklik, R. Piptori, J. Sieradzki, and R. Nizankowski, The effects of prostacyclin on glycemia and insulin release in man, Prostaglandins, 19: 959 (1980).
A. Szczeklik, J. Szczeklik, R. Nizankowski, and P. Gluszko, Prostacyclin for unstable angina, N. Engl. J. Med., 303: 881 (1980).
J. Szczeklik, J. S. Dubiel, M. Mysik, R. Król, and T. Horzela, Effedts of prostaglandin E1 on pulmonary circulation in patients with pulmonary hypertension, Br. Heart J., 40: 1397 (1978).
J. Szczeklik, A. Szczeklik, and effects of prostacyclin in man, Res., 7: 687 (1980).
J. Szczeklik, A. Szczeklik, and changes induced by prostacyclin (1980).
J. Szczeklik, A. Szczeklik, and R. Nizankowski, Prostacyclin for pulmonary hypertension, Lancet, 2: 1076 (1980).
J. E. Thompson and W. V. Garrett, Peripheral artery surgery, N. Engl. J. Med., 302: 491 (1979).
W. D. Watkins, M. P. Peterson, R. K. Brone, and L. Levine, Prostacyclin and prostaglandin E1 for severe pulmonary artery hypertension, Lancet, 1: 1083 (1980).
H. Źgulska-Mach, E. Kostka-Trabka, A Niton, and R. Gryglewski, Prostacyclin in central retinal vein occlusion, Lancet, 2: 1075 (1980).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Plenum Press, New York
About this chapter
Cite this chapter
Gryglewski, R.J., Szczeklik, A., Kostka-Trabka, E., Zygulska-Mach, H. (1983). Clinical Use of Prostacyclin in Vascular Disease. In: Berti, F., Folco, G., Velo, G.P. (eds) Leukotrienes and Prostacyclin. NATO Advanced Science Institutes Series, vol 54. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4391-2_18
Download citation
DOI: https://doi.org/10.1007/978-1-4684-4391-2_18
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-4393-6
Online ISBN: 978-1-4684-4391-2
eBook Packages: Springer Book Archive